A citation-based method for searching scientific literature

Carolyn E Haunschild, Krishnansu S Tewari. Future Oncol 2020
Times Cited: 11







List of co-cited articles
15 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
27

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
18

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
875
18

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
18

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Robert L Coleman, Gini F Fleming, Mark F Brady, Elizabeth M Swisher, Karina D Steffensen, Michael Friedlander, Aikou Okamoto, Kathleen N Moore, Noa Efrat Ben-Baruch, Theresa L Werner,[...]. N Engl J Med 2019
255
18

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
853
18


Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017
658
18

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
752
18

Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
Federica Tomao, Erlisa Bardhi, Anna Di Pinto, Carolina Maria Sassu, Elena Biagioli, Maria Cristina Petrella, Innocenza Palaia, Ludovico Muzii, Nicoletta Colombo, Pierluigi Benedetti Panici. Cancer Treat Rev 2019
32
18

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer,[...]. N Engl J Med 2019
437
18

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
K Abiko, N Matsumura, J Hamanishi, N Horikawa, R Murakami, K Yamaguchi, Y Yoshioka, T Baba, I Konishi, M Mandai. Br J Cancer 2015
361
18

Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.
A P M Heintz, F Odicino, P Maisonneuve, M A Quinn, J L Benedet, W T Creasman, H Y S Ngan, S Pecorelli, U Beller. Int J Gynaecol Obstet 2006
521
18

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma,[...]. J Clin Oncol 2015
627
18

Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Andrea R Hagemann, Akiva P Novetsky, Israel Zighelboim, Feng Gao, L Stewart Massad, Premal H Thaker, Matthew A Powell, David G Mutch, Jason D Wright. Gynecol Oncol 2013
19
18

A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.
Ashton C Berger, Anil Korkut, Rupa S Kanchi, Apurva M Hegde, Walter Lenoir, Wenbin Liu, Yuexin Liu, Huihui Fan, Hui Shen, Visweswaran Ravikumar,[...]. Cancer Cell 2018
215
9

What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Joyce F Liu, Ursula A Matulonis. Curr Oncol Rep 2016
17
9

Assessing the interactions between radiotherapy and antitumour immunity.
Clemens Grassberger, Susannah G Ellsworth, Moses Q Wilks, Florence K Keane, Jay S Loeffler. Nat Rev Clin Oncol 2019
62
9

Annual Report to the Nation on the Status of Cancer, Featuring Cancer in Men and Women Age 20-49 Years.
Elizabeth M Ward, Recinda L Sherman, S Jane Henley, Ahmedin Jemal, David A Siegel, Eric J Feuer, Albert U Firth, Betsy A Kohler, Susan Scott, Jiemin Ma,[...]. J Natl Cancer Inst 2019
123
9

Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.
Marcus E Randall, Virginia Filiaci, D Scott McMeekin, Vivian von Gruenigen, Helen Huang, Catheryn M Yashar, Robert S Mannel, Jae-Weon Kim, Ritu Salani, Paul A DiSilvestro,[...]. J Clin Oncol 2019
103
9

Using immunotherapy to boost the abscopal effect.
Wilfred Ngwa, Omoruyi Credit Irabor, Jonathan D Schoenfeld, Jürgen Hesser, Sandra Demaria, Silvia C Formenti. Nat Rev Cancer 2018
387
9

Cancer strikes the comic pages.
K Arnold. J Natl Cancer Inst 1999
5
20

Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.
Benjamin Y Jin, Tracy E Campbell, Lindsey M Draper, Sanja Stevanović, Bianca Weissbrich, Zhiya Yu, Nicholas P Restifo, Steven A Rosenberg, Cornelia L Trimble, Christian S Hinrichs. JCI Insight 2018
43
9

Endometrial cancer: Molecular markers and management of advanced stage disease.
Rebecca C Arend, Bayley A Jones, Alba Martinez, Paul Goodfellow. Gynecol Oncol 2018
69
9

Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma.
D G Decker, T R Fleming, G D Malkasian, M J Webb, J A Jeffries, J H Edmonson. Obstet Gynecol 1982
153
9



Ovarian cancer: screening and future directions.
Keshav Kumar Gupta, Vinay Kumar Gupta, Robert Wendel Naumann. Int J Gynecol Cancer 2019
22
9

Bevacizumab in ovarian cancer: A critical review of phase III studies.
Luigi Rossi, Monica Verrico, Eleonora Zaccarelli, Anselmo Papa, Maria Colonna, Martina Strudel, Patrizia Vici, Vincenzo Bianco, Federica Tomao. Oncotarget 2017
57
9

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
9

A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy.
Taymaa May, Robyn Comeau, Ping Sun, Joanne Kotsopoulos, Steven A Narod, Barry Rosen, Prafull Ghatage. Int J Gynecol Cancer 2017
20
9

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.
Deborah K Armstrong, Ronald D Alvarez, Jamie N Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S Berek, Lee-May Chen, Mihaela Cristea, Marie DeRosa,[...]. J Natl Compr Canc Netw 2019
95
9

Meta-analysis: state-of-the-science.
K Dickersin, J A Berlin. Epidemiol Rev 1992
353
9


Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
Panagiotis A Konstantinopoulos, Raphael Ceccaldi, Geoffrey I Shapiro, Alan D D'Andrea. Cancer Discov 2015
354
9

The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer.
Barry Rosen, Stephane Laframboise, Sarah Ferguson, Jason Dodge, Marcus Bernardini, Joan Murphy, Yakir Segev, Ping Sun, Steven A Narod. Gynecol Oncol 2014
71
9

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Amit M Oza, David Cibula, Ana Oaknin Benzaquen, Christopher Poole, Ron H J Mathijssen, Gabe S Sonke, Nicoletta Colombo, Jiří Špaček, Peter Vuylsteke, Holger Hirte,[...]. Lancet Oncol 2015
344
9

PARP-1 regulates DNA repair factor availability.
Matthew J Schiewer, Amy C Mandigo, Nicolas Gordon, Fangjin Huang, Sanchaika Gaur, Renée de Leeuw, Shuang G Zhao, Joseph Evans, Sumin Han, Theodore Parsons,[...]. EMBO Mol Med 2018
30
9

Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.
Shiyu Zhang, Robert Royer, Song Li, John R McLaughlin, Barry Rosen, Harvey A Risch, Isabel Fan, Linda Bradley, Patricia A Shaw, Steven A Narod. Gynecol Oncol 2011
246
9

A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy.
Helena C Bartels, Ailin C Rogers, Veronica McSharry, Ruaidhri McVey, Thomas Walsh, Donal O'Brien, William D Boyd, Donal J Brennan. Gynecol Oncol 2019
14
9

Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis.
Yanling Feng, He Huang, Ting Wan, Chuyao Zhang, Chongjie Tong, Jihong Liu. Adv Ther 2019
8
12

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
Julian P T Higgins, Douglas G Altman, Peter C Gøtzsche, Peter Jüni, David Moher, Andrew D Oxman, Jelena Savovic, Kenneth F Schulz, Laura Weeks, Jonathan A C Sterne. BMJ 2011
9

Some statistical methods for combining experimental results.
N M Laird, F Mosteller. Int J Technol Assess Health Care 1990
343
9

Prevalence and oncologic outcomes of BRCA1/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea.
Jun Hyeong Seo, Soo Young Jeong, Myeong Seon Kim, Jun Hyeok Kang, E Sun Paik, Yoo-Young Lee, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae,[...]. Obstet Gynecol Sci 2019
2
50

Clinical significance of ABCB1 genotyping in oncology.
Alma Hamidovic, Kristine Hahn, Jill Kolesar. J Oncol Pharm Pract 2010
37
9

VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer.
Apostolos Papachristos, Polychronis Kemos, Theodora Katsila, Eirini Panoilia, George P Patrinos, Haralabos Kalofonos, Gregory B Sivolapenko. Int J Mol Sci 2019
9
11

Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients.
Marie-Christine Etienne-Grimaldi, Patricia Formento, Armelle Degeorges, Jean-Yves Pierga, Rémi Delva, Xavier Pivot, Florence Dalenc, Marc Espié, Corinne Veyret, Jean-Louis Formento,[...]. Br J Clin Pharmacol 2011
56
9

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Josep Garcia, Herbert I Hurwitz, Alan B Sandler, David Miles, Robert L Coleman, Regula Deurloo, Olivier L Chinot. Cancer Treat Rev 2020
127
9

Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.
Matthias Pinter, Bernhard Scheiner, Markus Peck-Radosavljevic. Gut 2021
41
9

VEGF in Signaling and Disease: Beyond Discovery and Development.
Rajendra S Apte, Daniel S Chen, Napoleone Ferrara. Cell 2019
428
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.